Back

In HFrEF patients, reduced doses of sacubitril / valsartan do not result in increased mortality or heart failure hospitalizations compared to target dose. A retrospective cohort study

28 May 2018 (08:30 - 18:00)
Organised by:
Congress Presentation Part of: Poster Session 3 - Chronic Heart Failure – Treatment Pharmacotherapy HFA Premium Access Heart Failure 2018

About the speaker

Photo
Doctor Renato De Vecchis

Hospital San Gennaro - ASL Napoli 1 Centre, Naples (Italy)

38 More presentations in this session

Presentation thumbnail
Miss M. Vester (Leiden, NL)
Abstract Slides
Presentation thumbnail
Associate Professor O. Havakuk (Tel Aviv, IL)
Abstract
Presentation thumbnail
Professor Z. RAISSUNI (Tanger, MA)
Abstract
Presentation thumbnail
Presentation thumbnail

Access the full session

Session thumbnail
Poster Session 3 - Chronic Heart Failure – Treatment

The Event

Event poster

Heart Failure 2018

28 May 2018 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Evaluating tolerability and patient outcomes of sacubitril/valsartan for the management of heart failure with reduced ejection fraction within a pharmacist led clinic at a cardiovascular tertiary cent
29 June 2021
thumbnail
Congress Session
No time like the present: heart failure in the hospital setting
30 August 2024
thumbnail
Congress Presentation
Association between dose of medications and mortality in heart failure with reduced ejection fraction: a systematic review and dose-response meta-analysis
20 May 2023
thumbnail
Congress Presentation
Small reductions in NTproBNP levels in outpatients treated with sacubitril-valsartan reduce hospitalizations and emergency room visits.
29 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources